Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike is used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV2 spike protein. Pseudovirus display an antigenically-correct spike protein pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core.

Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike is capable of a single round of infection and carries a genome that expresses luciferase optical reporter gene upon infection. Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike are produced in HEK-293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene.

Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike are created using a second-generation lentiviral system with components that are highly unlikely to recombine to produce a fully infectious virus (requiring 3 separate recombination events to do so).

However, lentiviruses are capable of genomic integration, and pseudovirus is derived from biological materials so should be handled with caution within a BSL2 or enhanced BSL2 laboratory environment.

• Used in SARS-CoV-2 Pseudovirus Neutralization Assay.
• Safe in a BSL-2 environment.
• High infectivity titer
• Quantitative luciferase/GFP read-out
• Quality-controlled production for use as a critical reagent